Mangrove Partners Immunovant, Inc. Call Options Transaction History

Mangrove Partners

  • $936 Million
  • Q1 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$3.38 - $5.65 $751,712 - $1.26 Million
-222,400 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$5.06 - $8.77 $1.76 Million - $3.05 Million
-348,000 Reduced 61.01%
222,400 $1.23 Million
Q4 2021

Feb 14, 2022
SELL
$7.33 - $9.32 $4.17 Million - $5.31 Million
-569,500 Reduced 49.96%
570,400 $4.86 Million
Q3 2021

Nov 15, 2021
BUY
$7.01 - $11.37 $7.99 Million - $13 Million
1,139,900 New
1,139,900 $9.91 Million

Others Institutions Holding IMVT

# of Institutions
238
Shares Held
62.9M
Call Options Held
1.46M
Put Options Held
546K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Mangrove Partners Portfolio

Follow Mangrove Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

News

Stay updated on Mangrove Partners with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email